Shepherd Kaplan Krochuk’s Galectin Therapeutics GALT Stock Holding History

Shepherd Kaplan Krochuk’s Portfolio GALT Stock Details GALT Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2024 Q2	–	Sell	-12,000	Closed	-$28.7K	–	58
2024 Q1	$28.7K	Hold	12,000	–	–	0.02%	54
2023 Q4	$19.9K	Hold	12,000	–	–	0.02%	54
2023 Q3	$23K	Hold	12,000	–	–	0.02%	52
2023 Q2	$17.3K	Hold	12,000	–	–	0.01%	52
2023 Q1	$25.2K	Hold	12,000	–	–	0.02%	55
2022 Q4	$13.6K	Hold	12,000	–	–	0.01%	71
2022 Q3	$20K	Hold	12,000	–	–	0.01%	144
2022 Q2	$16K	Hold	12,000	–	–	0.01%	191
2022 Q1	$19K	Hold	12,000	–	–	0.01%	193
2021 Q4	$25K	Hold	12,000	–	–	0.01%	191
2021 Q3	$47K	Hold	12,000	–	–	0.02%	190
2021 Q2	$38K	Hold	12,000	–	–	0.01%	191
2021 Q1	$26K	Sell	12,000 -575	-5%	-$1.29K	0.01%	184
2020 Q4	$28K	Buy	12,575 +575	+5%	+$1.51K	0.01%	184
2020 Q3	$32K	Hold	12,000	–	–	0.01%	174
2020 Q2	$37K	Buy	+12,000	New	+$30.2K	0.02%	176

Other funds holding GALT

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

Osaic Holdings Scottsdale, Arizona $85.1B AUM 27.35% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

Commonwealth Equity Services Waltham, Massachusetts $79.5B AUM 27.1% 1-Year Est. Return

WANY

Wealthspire Advisors (New York) New York $18.2B AUM 21.48% 1-Year Est. Return

GWM

Geneos Wealth Management Englewood, Colorado $4.9B AUM 23.65% 1-Year Est. Return

State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return

AWS

Atria Wealth Solutions New York $4.42B AUM 16.4% 1-Year Est. Return

Shepherd Kaplan Krochuk's GALT Position: Q2 2024 in Review

Shepherd Kaplan Krochuk sold out of Galectin Therapeutics (GALT) in Q2 2024, closing a stake of 12,000 shares — an estimated $28.7K sold.

Shepherd Kaplan Krochuk first reported a position in GALT in Q2 2020 and held it in 16 quarters. The position peaked at $47K in Q3 2021. 73 funds tracked by Wall St. Rank hold GALT as of Q2 2024.

Shepherd Kaplan Krochuk reported no remaining Galectin Therapeutics position as of Q2 2024 after selling out during the quarter.
Shepherd Kaplan Krochuk sold 12,000 Galectin Therapeutics shares in Q2 2024, an estimated $28.7K.
Shepherd Kaplan Krochuk first reported a position in Galectin Therapeutics in Q2 2020 and held it in 16 quarters.
Shepherd Kaplan Krochuk's Galectin Therapeutics position peaked at $47K in Q3 2021.
73 funds tracked by Wall St. Rank held Galectin Therapeutics as of Q2 2024.

Based on Shepherd Kaplan Krochuk's 13F filing for Q2 2024, filed 14 Aug 2024.